MattsonJack Launches Syndicated Oncology Study

Kantar-owned pharma / biotech consultancy Mattson Jack Group has released a new syndicated study to help with decisions surrounding commercial opportunities in the field of oncology.

CancerNSight is a syndicated study that provides information to help decide whether a new product is worthy of development or an existing product's market position can be improved.

The tool contains in-depth data about product attributes and can be used to capture the perceptions and insights of key oncology opinion leaders (KOLs) and community treaters to help evaluate new products and regimens, especially the respective clinical attributes that drive and influence clinical decision-making.

The firm says the new tool is currently available for Non-Small Cell Lung Cancer studies, and it can be used in conjunction with MattsonJack's other 'knowledgeware' research tools, including CancerMPact, Oncology Marketing Strategies, Supportive Care Perspectives; and the firm's Future Focus series.

Formed in 1986, the company offers a combination of commercial and scientific expertise as well as market modelling and forecasting, and primary market research from its offices in Philadelphia, St Louis, San Francisco, Kansas City, Phoenix, London and Tokyo. In August, the firm promoted Dr Amit Dhawan to the role of Medical Director (www.mrweb.com/drno/news7209.htm ).

Web site: www.mattsonjack.com.

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Mattson Jack Group (MJG)
• All news